Trastuzumab emtansine versus Trastuzumab deruxtecan versus in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Sara A. Hurvitz, MD, UCLA Health discusses the released data for Phase 3 study entitled DESTINY-Breast03 at SABCS 2022
Advertisement